To our knowledge, this is the first study comprehensively describing the key roles of exerkine Fndc5/irisin in mediating therapeutic functions of NAD+-boosting therapy in metabolism disorders, further supporting the translational potential of NAD+-boosting molecules or irisin as exercise mimetics in clinical. The gene discussed is FNDC5; the disease is metabolic disease.